People living with HIV are more exposed to the adverse health effects of the worldwide COVID-19 pandemic. The pandemic's health and social repercussions may promote drug abuse and inadequate HIV management among this demographic. The coronavirus pandemic of 2019 (COVID-19) has caused unprecedented disruption worldwide in people's lives and health care. When the COVID-19 epidemic was identified, people with HIV faced significant obstacles and hurdles to achieving optimal care results. The viral spike protein (S-Protein) and the cognate host cell receptor angiotensin-converting enzyme 2 (ACE2) are both realistic and appropriate intervention targets. Calanolides A, Holy Basil, Kuwanon-L, and Patentiflorin have anti-HIV effects. Our computational biology study investigated that these compounds all had interaction binding scores related to S protein of coronavirus of -9.0 kcal /mol, -7.1 kcal /mol, -9.1 kcal /mol, and -10.3 kcal/mol/mol, respectively. A combination of plant-derived anti-HIV compounds like protease inhibitors and nucleoside analogs, which are commonly used to treat HIV infection, might be explored in clinical trials for the treatment of COVID-19.
Keywords: ACE2; ACE2, Angiotensin-converting enzyme-2; AIDS, Acquired immunodeficiency syndrome; AZT, Azidothymidine; CD4, Cluster of Differentiation 4; Calanolides A; Covid-19; HAART, Highly active antiretroviral therapy, ART, Antiretroviral therapy; HIV; HIV, Human Immunodeficiency Virus; Holy Basil; IN, Integrase; Kuwanon-L; NETs, neutrophil extracellular traps; NNTRIs, Non-nucleoside analogs transcriptase reverse inhibitor; NRTIs, nucleoside analog reverse transcriptase inhibitor; Patentiflorin A; RT, Reverse Transcriptase; S protein; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2.
© 2022 The Author(s).